INCX (6861) reported revenue of NT$240.3 million for Oct 2026, +4.1% year on year and -19.9% from the previous month. Revenue for Jan–Oct 2026 was NT$2.66 billion (+42.1% year on year).
Year-on-year revenue growth: 17 months in a row. →
In Oct 2026, it ranked No. 38 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$240.3 million | +4.1% | -19.9% |
| Sep 2026 | NT$299.9 million | +57.1% | +5.8% |
| Aug 2026 | NT$283.5 million | +52.5% | -2.5% |
| Jul 2026 | NT$290.8 million | +63.4% | +26.9% |
| Jun 2026 | NT$229.1 million | +12.6% | -13.8% |
| May 2026 | NT$265.7 million | +66.4% | +1.4% |
| Apr 2026 | NT$262.2 million | +39.7% | -4.4% |
| Mar 2026 | NT$274.3 million | +52.6% | +5.5% |
| Feb 2026 | NT$260.1 million | +44.0% | +1.3% |
| Jan 2026 | NT$256.7 million | +45.5% | +18.3% |
| Dec 2025 | NT$217 million | +6.1% | +6.5% |
| Nov 2025 | NT$203.6 million | +18.4% | -11.8% |
| Oct 2025 | NT$230.8 million | +43.1% | +20.9% |
| Sep 2025 | NT$190.9 million | +14.5% | +2.7% |
| Aug 2025 | NT$185.9 million | +24.0% | +4.5% |
| Jul 2025 | NT$178 million | +6.6% | -12.5% |
| Jun 2025 | NT$203.5 million | +23.1% | +27.4% |
| May 2025 | NT$159.7 million | -7.8% | -14.9% |
| Apr 2025 | NT$187.6 million | +9.4% | +4.4% |
| Mar 2025 | NT$179.8 million | +18.6% | -0.5% |
| Feb 2025 | NT$180.6 million | +27.6% | +2.4% |
| Jan 2025 | NT$176.4 million | +6.8% | -13.7% |
| Dec 2024 | NT$204.5 million | +18.4% | +18.9% |
| Nov 2024 | NT$172 million | +5.5% | +6.6% |
| Oct 2024 | NT$161.3 million | -4.7% | -3.3% |
Jan–Oct 2026 cumulative: NT$2.66 billion (+42.1% YoY)
Other Biotech & Medical companies
Compare with peers: INCX vs PEC / INCX vs Lotus Pharm / INCX vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16